Foghorn Therapeutics

Update in progress

FHTX (NasdaqGM)

Company RatingNeutral
SectorHealthcare
IndustryBiotechnology

Foghorn Therapeutics is a clinical‑stage biopharmaceutical company focused on medicines that target genetically driven dependencies in the chromatin regulatory system. Using its Gene Traffic Control platform, it discovers and validates drug Targets within this system. Foghorn is developing therapies for various cancers, including mutant, non-small cell lung, endometrial, cervical, ovarian, and bladder cancers, and certain blood cancers. It collaborates with Eli Lilly on FHD-909, a selective BRM ATPase inhibitor. Founded in 2015, it is based in Watertown, Massachusetts.

Company score

Sentiment: 0.31; SentimentMeasures the overall tone of recent coverage and discussion about the company.−10 negative · 0 neutral · +10 positive
Environment: 0.00; EnvironmentAssesses the company’s environmental impact, risks, and sustainability practices.−10 negative · 0 neutral · +10 positive
Social: 0.00; SocialAssesses the company’s influence on employees, customers, communities, and wider society.−10 negative · 0 neutral · +10 positive
Governance: 0.03; GovernanceAssesses leadership, accountability, transparency, and business ethics.−10 negative · 0 neutral · +10 positive
Sustainability: 0.01; SustainabilityCombines environmental, social, and governance signals into an overall sustainability score.−10 negative · 0 neutral · +10 positive
Impact Score: 0.16; Impact ScoreCombines sentiment and sustainability performance into an assessment of the company’s overall impact.−10 negative · 0 neutral · +10 positive